







an Open Access Journal by MDPI

# Chronic Kidney Disease and Acute Kidney Injury in the COVID-19 Era: In the Search for New Biomarkers to Improve Decision Making

Guest Editors:

Prof. Dr. Francisco Herrera-Gómez

Prof. Dr. F. Javier Álvarez

Dr. Gabriella Guzzo

Prof. Dr. Daniel Teta

Deadline for manuscript submissions:

closed (31 October 2021)

## **Message from the Guest Editors**

With the objective of a more individualized decision-making process concerning individuals with CKD and AKI in this new era marked by the pandemic, which is rapidly evolving with the advent of vaccines, this Special Issue entitled "Chronic Kidney Disease and Acute Kidney Injury in the COVID-19 Era: In the Search for New Biomarkers to Improve Decision Making" aims to compile original research articles and review articles on all potential candidates to prognostic biomarkers for these patients.













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

## **Message from the Editor-in-Chief**

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

#### **Contact Us**